© Springer-Verlag Berlin Heidelberg 2014
10.1007/s13539-014-0148-8

Left ventricular mass correlates with lean body mass in patients with disease-associated wasting

Alessio Molfino1, Alessia Papa1, Maria L. Gasperini-Zacco1, Maurizio Muscaritoli1, Antonio Amoroso1, Antonia Cascino1, Carlo Catalano2, Carlina V. Albanese2 and Alessandro Laviano 
(1)
Department of Clinical Medicine, Sapienza University, viale dell’Università 37, 00185 Rome, Italy
(2)
Department of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University, Rome, Italy
 
 
Alessandro Laviano
Received: 10 April 2014Accepted: 5 May 2014Published online: 5 June 2014
Without Abstract
Alessio Molfino and Alessia Papa contributed equally to the work.
Dear Editor,
The key feature of disease-associated malnutrition, or cachexia, is muscle wasting [1]. However, an efficient tool for the assessment of skeletal muscularity in daily practice is not available yet [2]. We recently demonstrated that left ventricular mass (LVM) as measured by echocardiography reflects nutritional status in patients with systemic sclerosis [3]. Similarly to skeletal muscles, cardiac myofibrils contain actin and myosin, and mitochondria are largely represented in the heart [4]. Therefore, cachexia and heart failure may evolve concurrently during disease [5]. To preliminarily explore the relationship between cachexia and heart failure, we assessed whether LVM correlates to whole body skeletal muscle mass in cachectic, hospitalized patients.
Adult patients admitted to our institution and meeting the definition of cachexia by Fearon et al. [1] were considered. Patients unable to give informed consent, with gastrointestinal obstruction or dysphagia, with acute or chronic heart failure, or with history of high blood pressure were excluded. Patients’ lean body mass (LBM) was assessed by dual-energy X-ray absorptiometry (DXA; GE Lunar Prodigy; Madison, WI, USA). Internal diameter of left ventricle (LVID), thickness of the posterior wall (PWT), and thickness of the interventricular septum (SWT) were measured in M-mode, during the diastolic phase [6], by echocardiography (Toshiba Aplio 500; Toshiba, Italy, Rome) with a 3.75-MHz probe. Then, cardiac mass was calculated using the Devereux formula [7, 8]:
LVM(g)=0.8×(1.04[(LVIDd×PWTd×SWTd)3(LVIDd)3])+0.6.
Data obtained were then normalized by patients’ body surface and are expressed as grams per square meter. Handgrip strength was also assessed (DynEx, Akern, Florence, Italy). Patients’ anthropometry (weight, height, BMI) and biochemistry were collected from charts and recorded. Data have been analyzed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). Data are presented as M ± SD.
Patients’ characteristics are reported in Table 1. Mean absolute and normalized LVM were 117.3 ± 47 g and 76.8 ± 20.8 g/m2, respectively. Mean lean body mass (LBM) was 34.0 ± 7.1 kg. Absolute (Fig. 1) and normalized LVM correlated with LBM [r = 0.971 and r = 0.931, respectively; p < 0.01]. Furthermore, LVM was correlated with circulating creatinine levels (r = 0.868, p < 0.01). No correlation was found between LVM and handgrip strength.
Table 1
Patients’ characteristics
Sex (M:F)
13:1
Age (years)
58.0 ± 20.4
Body weight (kg)
48.6 ± 12.2
BMI
18.7 ± 3.6
Albumin (g/dL)
3.7 ± 0.51
Blood protein level (g/dL)
6.0 ± 1.0
Body weight loss in the previous 6 months (kg)
7.6 ± 8
Handgrip strength (kg)
19.4 ± 7.5
Advanced cancer/chronic renal failure/pneumonia (n)
10/3/1
/static-content/images/444/art%253A10.1007%252Fs13539-014-0148-8/MediaObjects/13539_2014_148_Fig1_HTML.gif
Fig. 1
Correlation between LVM and LBM
Our preliminary study shows that in cachectic patients, LVM correlates with LBM and serum creatinine, a recognized maker of muscularity [9]. Our results are consistent with previous animal studies showing that cancer causes a loss of cardiac mass [10] and that cancer-induced muscle loss is paralleled by similar reduction of heart’s weight [11]. In humans, data are more scanty. Recently, Springer et al. showed that heart weight and left ventricle wall thickness are reduced in cancer patient [12]. Our study should be considered preliminary but strongly encourages the initiation of larger trials to assess the evolution heart mass and function during the clinical journey of cachexia.
Acknowledgments
The authors certify that they comply with the ethical guidelines for authorship and publishing of the Journal of Cachexia, Sarcopenia and Muscle (von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle 2010; 1:7–8).
Conflict of interest statement
Alessio Molfino, Alessia Papa, Maria L. Gasperini-Zacco, Maurizio Muscaritoli, Antonio Amoroso, Antonia Cascino, Carlo Catalano, Carlina V. Albanese, and Alessandro Laviano declare that they have no conflict of interest.
References
1.
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.PubMedCrossRef
2.
Silver HJ, Welch EB, Avison MJ, Niswender KD. Imaging body composition in obesity and weight loss: challenges and opportunities. Diabetes Metab Syndr Obes. 2010;3:337–47.PubMedCentralPubMedCrossRef
3.
Rosato E, Gigante A, Gasperini ML, Molinaro I, Di Lazzaro GG, Afeltra A, et al. Nutritional status measured by BMI is impaired and correlates with left ventricular mass in patients with systemic sclerosis. Nutrition. 2014;30:204–9.PubMedCrossRef
4.
Willis MS, Schisler JC, Portbury AL, Patterson C. Build it up-tear it down: protein quality control in the cardiac sarcomere. Cardiovasc Res. 2009;81:439–48.PubMedCentralPubMedCrossRef
5.
Kazemi-Bajestani SM, Becher H, Fassbender K, Chu Q, Baracos VE. Concurrent evolution of cancer cachexia and heart failure: bilateral effects exists. J Cachexia Sarcopenia Muscle. 2014. doi:10.​1007/​s13539-014-0137-y.PubMed
6.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79–108.PubMedCrossRef
7.
Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55:613–8.PubMedCrossRef
8.
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–8.PubMedCrossRef
9.
Streja E, Molnar MZ, Kovesdy CP, Bunnapradist S, Jing J, Nissenson AR, et al. Associations of pretransplant weight and muscle mass with mortality in renal transplant recipients. Clin J Am Soc Nephrol. 2011;6:1463–73.PubMedCentralPubMedCrossRef
10.
Cosper PF, Leinwand LA. Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. Cancer Res. 2011;71:1710–20.PubMedCentralPubMedCrossRef
11.
Palus S, von Haehling S, Flach VC, Tschirner A, Doehner W, Anker SD, et al. Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia. Int J Cardiol. 2013;168:3412–8.PubMedCrossRef
12.
Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, Grzesiak A, et al. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J. 2013. doi:10.​1093/​eurheartj/​eht302.
Journal of Cachexia, Sarcopenia and Muscle